First Health United is a non-profit organization based in The Netherlands. We are a fully independent spin off of the company First Health Pharmaceuticals, who transferred the largest part of its antivirus development pipeline to our non-profit foundation.
We develop revolutionary new antiviral agents based on an existing portfolio of highly active pharmaceutical compounds that was granted to our organization by our sponsor First Health Pharmaceuticals.
A Revolutionary Approach
Setback in Dengue vaccine program
It was announced that the use of the only approved Dengue vaccine, Dengvaxia, is to be strictly limited due to evidence it can worsen the disease in people who have not previously been exposed to the infection. The bad news is a setback for the millions of people that still suffer Dengue infections worldwide.
First Health Pharmaceuticals took its Social Responsibility very serious when it donated the largest part of its antivirus pipeline to First Health United. The decision is testimony to the fact that profit maximisation is clearly not the only goal of the company and that Social Responsibility is a driving force within the First Health group.
We are Different
Most non-profit organisations work at a national level, gravitating towards basic research in their country of origin. First Health United is different: We collaborate with whatever university is a leader in our field of research, regardless if it is in the Netherlands, China, Italy or the USA.
Your contribution will save lives
You can contribute to the development and non-profit distribution of tangible new pharmaceuticals.
You can help saving tens of thousands of lives each year. Your donations will directly support First Health United Foundation’s commitment of development and non-profit distribution of tangible new pharmaceuticals that are effective against crippling infectious viral diseases.
Besides the Dengue Project, First Health United is investigating cures for other viral diseases. It also offers the possibility to sponsor specific scholarships targeting the development of new antivirus agents against a specific disease.